Format

Send to

Choose Destination
Gastric Cancer. 2016 Jan;19(1):31-41. doi: 10.1007/s10120-015-0537-5. Epub 2015 Sep 2.

Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.

Author information

1
Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy. giandomenicoroviello@hotmail.it.
2
Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
3
Unit of General and Minimally Invasive Surgery, Department of Medical, Surgical and Neuroscience, University of Siena, Viale Bracci 11, Siena, 53100, Italy.
4
Section of Advanced Surgical Oncology, Department of Medical, Surgical and Neurosciences, University of Siena, Viale Bracci 11, Siena, 53100, Italy.

Abstract

Despite significant improvements in systemic chemotherapy during the past two decades, the prognosis of patients with advanced gastric and gastroesophageal junction adenocarcinoma remains poor. Because of molecular heterogeneity, it is essential to classify tumors based on the underlying oncogenic pathways and to develop targeted therapies acting on individual tumors. Unfortunately, although a number of molecular targets have been studied, very few of these agents can be used in a clinical setting. In this review, we summarize the available data on anti-angiogenic agents in advanced/metastatic gastric cancer.

KEYWORDS:

Bevacizumab; Gastric cancer; Ramucirumab; VEGF

PMID:
26329368
DOI:
10.1007/s10120-015-0537-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center